Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029581> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4377029581 endingPage "A8" @default.
- W4377029581 startingPage "A7.3" @default.
- W4377029581 abstract "Introduction Favipiravir selectively inhibits RNA polymerase responsible for single-stranded viral replication. It is licensed for treating influenza and repurposed to treat other diseases such as Ebola and COVID-19. It is metabolised by hepatic aldehyde oxidase (AO) and is an AO inhibitor with complex pharmacokinetics. We have used favipiravir, in combination with other antivirals, in severely immunocompromised children with life-threatening RNA virus infections. As an unlicensed indication, favipiravir pharmacokinetics were routinely monitored at our institution. Population pharmacokinetic model is used to describe the favipiravir pharmacokinetic properties, drug exposure and sources of variability in these children. Methods Routine favipiravir plasma levels of 9 patients (0.8–11yrs, mean age=5.3yrs; median weight=15kg) were analysed retrospectively (62 samples). All patients received favipiravir 200mg or 400mg tds and had at least one plasma level 45min (peak), 3h and 8h (trough) post-dose. Parameter estimation and model simulation properties (visual predictive check) were assessed using R language (v 4.1.2) and RStudio (2022.02.0+443). Results A one-compartment model with weight as covariate best describes the data, with (1) elimination clearance=1L/h and volume of distribution=7.54L, both allometric scaled centring at median weight, and (2) estimated t1/2=5.17h with Cmax = 24µg/mL at 200mg and 41µg/mL at 400mg. Conclusions To our knowledge this is the first report of favipiravir pharmacokinetic parameters in infants and young children. Weight significantly improves the model fit as a covariate. Reported EC50 for norovirus in vitro was 19–39µg/mL and enterovirus 71 was 23µg/mL, indicating higher favipiravir doses or combination with other antivirals are required." @default.
- W4377029581 created "2023-05-19" @default.
- W4377029581 creator A5019677924 @default.
- W4377029581 creator A5043046164 @default.
- W4377029581 creator A5045396101 @default.
- W4377029581 creator A5069317379 @default.
- W4377029581 creator A5070647783 @default.
- W4377029581 creator A5086351311 @default.
- W4377029581 date "2023-05-18" @default.
- W4377029581 modified "2023-09-28" @default.
- W4377029581 title "22 Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections" @default.
- W4377029581 doi "https://doi.org/10.1136/archdischild-2023-esdppp.22" @default.
- W4377029581 hasPublicationYear "2023" @default.
- W4377029581 type Work @default.
- W4377029581 citedByCount "0" @default.
- W4377029581 crossrefType "journal-article" @default.
- W4377029581 hasAuthorship W4377029581A5019677924 @default.
- W4377029581 hasAuthorship W4377029581A5043046164 @default.
- W4377029581 hasAuthorship W4377029581A5045396101 @default.
- W4377029581 hasAuthorship W4377029581A5069317379 @default.
- W4377029581 hasAuthorship W4377029581A5070647783 @default.
- W4377029581 hasAuthorship W4377029581A5086351311 @default.
- W4377029581 hasBestOaLocation W43770295811 @default.
- W4377029581 hasConcept C112705442 @default.
- W4377029581 hasConcept C126322002 @default.
- W4377029581 hasConcept C139254425 @default.
- W4377029581 hasConcept C142462285 @default.
- W4377029581 hasConcept C159047783 @default.
- W4377029581 hasConcept C2522874641 @default.
- W4377029581 hasConcept C2778414717 @default.
- W4377029581 hasConcept C2779134260 @default.
- W4377029581 hasConcept C2779298103 @default.
- W4377029581 hasConcept C2779772310 @default.
- W4377029581 hasConcept C2993143319 @default.
- W4377029581 hasConcept C3008058167 @default.
- W4377029581 hasConcept C524204448 @default.
- W4377029581 hasConcept C71924100 @default.
- W4377029581 hasConcept C98274493 @default.
- W4377029581 hasConceptScore W4377029581C112705442 @default.
- W4377029581 hasConceptScore W4377029581C126322002 @default.
- W4377029581 hasConceptScore W4377029581C139254425 @default.
- W4377029581 hasConceptScore W4377029581C142462285 @default.
- W4377029581 hasConceptScore W4377029581C159047783 @default.
- W4377029581 hasConceptScore W4377029581C2522874641 @default.
- W4377029581 hasConceptScore W4377029581C2778414717 @default.
- W4377029581 hasConceptScore W4377029581C2779134260 @default.
- W4377029581 hasConceptScore W4377029581C2779298103 @default.
- W4377029581 hasConceptScore W4377029581C2779772310 @default.
- W4377029581 hasConceptScore W4377029581C2993143319 @default.
- W4377029581 hasConceptScore W4377029581C3008058167 @default.
- W4377029581 hasConceptScore W4377029581C524204448 @default.
- W4377029581 hasConceptScore W4377029581C71924100 @default.
- W4377029581 hasConceptScore W4377029581C98274493 @default.
- W4377029581 hasIssue "6" @default.
- W4377029581 hasLocation W43770295811 @default.
- W4377029581 hasOpenAccess W4377029581 @default.
- W4377029581 hasPrimaryLocation W43770295811 @default.
- W4377029581 hasRelatedWork W1901877366 @default.
- W4377029581 hasRelatedWork W1978783304 @default.
- W4377029581 hasRelatedWork W2010112829 @default.
- W4377029581 hasRelatedWork W2032959558 @default.
- W4377029581 hasRelatedWork W2141774967 @default.
- W4377029581 hasRelatedWork W2155109292 @default.
- W4377029581 hasRelatedWork W2171197182 @default.
- W4377029581 hasRelatedWork W3110119473 @default.
- W4377029581 hasRelatedWork W3196151055 @default.
- W4377029581 hasRelatedWork W4377029581 @default.
- W4377029581 hasVolume "108" @default.
- W4377029581 isParatext "false" @default.
- W4377029581 isRetracted "false" @default.
- W4377029581 workType "article" @default.